Strategic Collaboration, Option and License Agreement Between Akcea Therapeutics, Inc. And Novartis Pharma AGStrategic Collaboration, Option and License Agreement • May 9th, 2017 • Ionis Pharmaceuticals Inc • Pharmaceutical preparations • New York
This STRATEGIC COLLABORATION, OPTION AND LICENSE AGREEMENT (the “Agreement”) is entered into as of the 5th day of January, 2017 (the “Execution Date”) by and between Akcea Therapeutics, Inc., a Delaware corporation, having its principal place of business at 55 Cambridge Parkway, Cambridge, MA 02142 USA, together with each of Akcea’s Affiliates (“Akcea”), andNovartis Pharma AG, a company organized under the laws of Switzerland, having its principal place of business at Lichtstrasse 35, 4002 Basel, Switzerland (“Novartis”). Novartis and Akcea each may be referred to herein individually as a “Party” or collectively as the “Parties.” Capitalized terms used in this Agreement, whether used in the singular or the plural, have the meaning set forth in Appendix 1. All attached appendices and schedules are a part of this Agreement. As of the Effective Date, Akcea is a wholly-owned subsidiary of Ionis Pharmaceuticals, Inc. (“Ionis”) and therefore Akcea and Ionis are Affiliates.
STOCK PURCHASE AGREEMENTStock Purchase Agreement • May 9th, 2017 • Ionis Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
This Stock Purchase Agreement (“Agreement”) is entered into as of January 5, 2017 (the “Execution Date”), by and among Novartis Pharma AG (“Novartis”), a company organized under the laws of Switzerland, having its principal place of business at Lichtstrasse 35, 4002 Basel, Switzerland, Ionis Pharmaceuticals, Inc. (“Ionis”), a Delaware corporation having its principal place of business at 2855 Gazelle Court, Carlsbad, CA 92010, and Akcea Therapeutics, Inc. (“Akcea”), a Delaware corporation having its principal place of business at 55 Cambridge Parkway, Suite 100, Cambridge, MA 02142.
AMENDMENT #1License Agreement • May 9th, 2017 • Ionis Pharmaceuticals Inc • Pharmaceutical preparations
This AMENDMENT #1 ("Amendment #1") is entered into as of February 10, 2017 (the "Amendment Date") by and between Ionis Pharmaceuticals, Inc. (formerly named Isis Pharmaceuticals, Inc.), a Delaware corporation, having its principal place of business at 2855 Gazelle Court, Carlsbad, CA 92010, USA (“Ionis”), and Bayer AG (upon assignment by Bayer Pharma AG effective January 1, 2017), a company organized under the Laws of Germany, whose office is situated at Muellerstraße 178, 13353 Berlin, Germany (“Bayer”).
